Despite the fact that several NLRP3 inflammasome inhibitors have been developed, further basic and clinical research is needed for a better understanding of inflammasomes and for the development of effective therapeutic strategies for both the prevention and treatment of inflammatory, metabolic, neurological and cardiovascular diseases, which have inflammasomes among the main causes. This evidence concerns the gene NLRP3 and cardiovascular disorder.